Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Fueling Labor: Protein Supplementation for Intrapartum Glucose Control

29. dubna 2026 aktualizováno: Brock E. Polnaszek, MD MPH, Medical College of Wisconsin

Fueling Labor: A Pilot Randomized Controlled Trial of High-Protein Supplementation During Labor to Improve Glucose Control in Insulin-Treated Diabetes Using Continuous Glucose Monitoring

The goal of this study is to learn if high-protein drinks during labor can improve blood sugar control in pregnant women with insulin-treated diabetes. It will also help us learn if this approach is acceptable and well-tolerated by patients. The main questions it aims to answer are:

  • Does drinking high-protein beverages during labor keep blood sugar in a healthier range compared to drinking standard clear liquids?
  • How do participants feel about drinking protein beverages during labor, and does it affect their energy levels and birth experience?
  • Is the baby less likely to have low blood sugar after birth when the mother drinks protein beverages during labor?

Researchers will compare women who drink high-protein beverages to women who drink standard clear liquids (like juice, broth, and popsicles) to see if protein drinks help keep blood sugar more stable during labor.

Participants will:

  • Wear a small, painless glucose sensor on their arm from when labor starts until about one week after giving birth
  • Be randomly assigned to either drink a clear protein beverage every 4 hours during labor OR drink standard clear liquids as usual
  • Complete short surveys about how tired they feel during labor, their overall birth experience, and their overall experience with the glucose sensor

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Background and Rationale:

Optimal nutrition during labor for patients with insulin-treated diabetes in pregnancy remains poorly defined. While current guidelines support clear liquid intake during labor, the metabolic effects of different nutritional strategies-particularly high-protein supplementation-have not been studied. Maintaining stable maternal glucose levels during labor is essential to reducing neonatal complications, including hypoglycemia. However, standard clear liquids may cause glucose excursions, while prolonged fasting may contribute to maternal fatigue and metabolic stress.

Continuous glucose monitoring (CGM) technology provides real-time assessment of glucose patterns during labor, offering a novel opportunity to evaluate how targeted nutritional interventions influence maternal glycemic stability. Recent evidence suggests that maternal time above glucose target range during labor is associated with neonatal hypoglycemia, yet no studies have examined whether protein-based oral supplementation can improve intrapartum glucose control compared to standard clear liquids.

Study Objectives:

This pilot randomized controlled trial evaluates the feasibility and metabolic impact of high-protein oral supplementation during labor in patients with insulin-treated gestational or type 2 diabetes undergoing induction of labor. The study aims to:

  1. Assess feasibility and acceptability of implementing a CGM-guided intrapartum nutritional protocol
  2. Compare CGM-derived glycemic metrics (including percent time above range >110 mg/dL, time in range, and glycemic excursions) between high-protein supplementation and standard clear liquids
  3. Explore associations with maternal experience (fatigue, birth satisfaction) and neonatal outcomes

Study Design:

Sixty participants with insulin-treated gestational diabetes (GDM A2) or type 2 diabetes will be randomized 1:1 to receive either high-protein nutritional supplements (30g protein, 0g carbohydrate) every 4 hours during labor or standard institutional clear liquid diet. All participants will wear a blinded CGM (Abbott Freestyle Libre) from admission through delivery and for up to 7 days postpartum. The primary outcome is percent time above glucose range (>110 mg/dL) during labor. Secondary outcomes include other CGM metrics, maternal fatigue and satisfaction scores, labor outcomes, and neonatal hypoglycemia.

Significance:

This pilot study will generate critical preliminary data on the metabolic effects, patient-centered outcomes, and feasibility of high-protein intrapartum supplementation, informing the design of future larger trials to optimize evidence-based nutritional management during labor for patients with insulin-treated diabetes.

Typ studie

Intervenční

Zápis (Odhadovaný)

60

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

  • Spojené státy
    • Wisconsin
      • Milwaukee, Wisconsin, Spojené státy, 53226
        • Froedtert Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Age ≥18 years
  • Singleton pregnancy
  • Gestational age ≥37 0/7 weeks at time of induction
  • Diagnosis of gestational diabetes requiring insulin therapy (GDM A2) or pre-existing Type 2 diabetes managed with insulin during pregnancy
  • Admission to labor and delivery for induction of labor
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Multifetal gestation
  • Major fetal anomalies or conditions affecting neonatal glucose regulation
  • Stillbirth
  • Planned cesarean delivery
  • Inability to provide consent
  • Contraindication to oral intake (e.g., NPO status for clinical indication)
  • Known allergy or intolerance to study materials, including components of the high-protein supplement or CGM device

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Prevence
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: High-Protein Supplementation
Participants will be offered Genius Gourmet Sparkling Protein Water (approximately 30 g protein, 0 g carbohydrate, 0 g fat, 130 kcal per 12-ounce serving) every 4 hours beginning at randomization until delivery. Consumption is voluntary. All participants will wear a blinded CGM from admission through 7 days postpartum.
Doplněk stravy: High-Protein Beverage (Genius Gourmet Sparkling Protein Water)
Clear, carbonated, commercially available high-protein nutritional supplement containing approximately 30 g protein, 0 g carbohydrate, 0 g fat, and 130 kcal per 12-ounce serving. Offered every 4 hours during labor. Multiple flavors available (participant's choice).
Přístroj: Continuous Glucose Monitoring (Abbott Freestyle Libre)
Abbott Freestyle Libre 2 or Libre 3 CGM sensor placed on upper arm upon admission. Sensor remains in place through delivery and up to 7 days postpartum. CGM data blinded to participants and clinical staff during labor.
Aktivní komparátor: Standard Clear Liquid Diet
Participants will receive standard institutional clear liquid diet (water, ice chips, clear fruit juices, clear carbonated beverages, popsicles, clear broth, gelatin) ad libitum throughout labor per routine institutional practice. All participants will wear a blinded CGM from admission through 7 days postpartum.
Přístroj: Continuous Glucose Monitoring (Abbott Freestyle Libre)
Abbott Freestyle Libre 2 or Libre 3 CGM sensor placed on upper arm upon admission. Sensor remains in place through delivery and up to 7 days postpartum. CGM data blinded to participants and clinical staff during labor.
Jiný: Standard Clear Liquid Diet
Standard institutional clear liquid diet including water, ice chips, clear fruit juices (e.g., apple juice), clear carbonated beverages (e.g., ginger ale), popsicles, clear broth, and gelatin. Carbohydrate-containing clear liquids permitted per standard practice.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percent Time Above Range (TAR >110 mg/dL) During Labor
Časové okno: From admission to delivery (expected ≤72 hours)
Percentage of CGM readings exceeding 110 mg/dL during labor, calculated as the proportion of valid CGM readings >110 mg/dL divided by total valid readings, expressed as a percentage.
From admission to delivery (expected ≤72 hours)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time in Range
Časové okno: From admission to delivery (expected ≤72 hours)
Percentage of CGM readings within target range during labor (70-110 mg/dL)
From admission to delivery (expected ≤72 hours)
Glycemic Variability
Časové okno: From admission to delivery (expected ≤72 hours)
Standard deviation and coefficient of variation of CGM glucose values during labor.
From admission to delivery (expected ≤72 hours)
Hyperglycemic Excursions
Časové okno: From admission to delivery (expected ≤72 hours)
Number of episodes of CGM glucose >140 mg/dL, separated by ≥15 minutes below threshold.
From admission to delivery (expected ≤72 hours)
Hypoglycemic Events
Časové okno: From admission to delivery (expected ≤72 hours)
Number of CGM glucose values <70 mg/dL during labor.
From admission to delivery (expected ≤72 hours)
Total Insulin Use During Labor
Časové okno: From admission to delivery (expected ≤72 hours)
Total insulin administered (units)
From admission to delivery (expected ≤72 hours)
Maternal Fatigue Score (VAS)
Časové okno: Admission and every 4 hours until delivery (expected ≤72 hours)
Visual Analog Scale for fatigue (0-10), where higher scores indicate greater fatigue.
Admission and every 4 hours until delivery (expected ≤72 hours)
Labor Agentry Scale Score (LAS)
Časové okno: 24-48 hours postpartum
Labor Agentry Scale (LAS), a 29-item validated measure of perceived control during labor. Each item is scored on a 7-point Likert scale. Total scores range from 29 to 203, with higher scores indicating greater perceived control.
24-48 hours postpartum
Birth Satisfaction Scale-Revised Score
Časové okno: 24-48 hours postpartum
A 10-item validated measure of overall birth satisfaction. Each item is scored on a 0-4 scale. Total scores range from 0 to 40, with higher scores indicating greater birth satisfaction.
24-48 hours postpartum
Maternal Emesis
Časové okno: From admission to delivery (expected ≤72 hours)
Number of vomiting episodes during labor documented by clinical record or participant report.
From admission to delivery (expected ≤72 hours)
Mode of Delivery
Časové okno: At delivery
Mode of delivery categorized as spontaneous vaginal, operative vaginal, or cesarean delivery.
At delivery
Neonatal Hypoglycemia
Časové okno: First 24 hours of life
Blood glucose <40 mg/dL.
First 24 hours of life
Neonatal Intensive Care Unit (NICU) Admission
Časové okno: From birth through hospital discharge (expected ≤28 days)
Admission to neonatal intensive care unit (yes/no).
From birth through hospital discharge (expected ≤28 days)
Neonatal Glucose Supplementation
Časové okno: First 24 hours of life
Requirement for oral or IV glucose.
First 24 hours of life
Postpartum Time in Range
Časové okno: Delivery to 7 days postpartum
Percentage of CGM readings within postpartum target range (70-140 mg/dL).
Delivery to 7 days postpartum
Composite Maternal Morbidity
Časové okno: Up to 6 weeks postpartum
Composite maternal morbidity defined as occurrence of any of the following conditions: postpartum hemorrhage requiring intervention such as estimated blood loss >1000 milliliters (mL) or uterotonics, tranexamic acid, blood transfusion or surgical interventions (dilation and curettage, Bakri, Jada, laparotomy, interventional radiology), endometritis, intraamniotic infection, obstetric anal sphincter injury (OASIS), ICU admission, amniotic fluid embolism, and death.
Up to 6 weeks postpartum
Umbilical Cord Blood Gas Values
Časové okno: At delivery
Umbilical arterial cord blood gas values (pH, partial pressure of carbon dioxide (pCO₂), and base excess)
At delivery
Infant Healthcare Utilization
Časové okno: Birth to 1 year of life
Healthcare utilization including hospitalizations, emergency department visits, urgent care visits, and primary care visits assessed via medical record and parental report.
Birth to 1 year of life
Labor Duration
Časové okno: From admission to delivery (expected ≤72 hours)
Duration of first, second, and third stages of labor measured in hours
From admission to delivery (expected ≤72 hours)
Infant Weight
Časové okno: Birth to 1 year of life
Infant weight in kilograms
Birth to 1 year of life
Infant Length
Časové okno: Birth to 1 year of life
Infant length in centimeters
Birth to 1 year of life
NICU Length of Stay
Časové okno: From birth through hospital discharge (expected ≤28 days)
Duration of NICU hospitalization measured in days.
From birth through hospital discharge (expected ≤28 days)
Respiratory Support
Časové okno: From birth through hospital discharge (expected ≤28 days)
Requirement for respiratory support including supplemental oxygen, continuous positive airway pressure (CPAP), or mechanical ventilation (intubation).
From birth through hospital discharge (expected ≤28 days)
Neonatal Jaundice Requiring Phototherapy
Časové okno: From birth through hospital discharge (expected ≤28 days)
Need for phototherapy for neonatal hyperbilirubinemia.
From birth through hospital discharge (expected ≤28 days)
Neonatal Hypoglycemia Treatment
Časové okno: From birth through hospital discharge (expected ≤28 days)
Requirement for glucose supplementation (oral or intravenous).
From birth through hospital discharge (expected ≤28 days)
Neonatal Sepsis
Časové okno: From birth through hospital discharge (expected ≤28 days)
Documented clinical suspicion or laboratory-confirmed neonatal sepsis.
From birth through hospital discharge (expected ≤28 days)
Perinatal Death
Časové okno: From birth through hospital discharge (expected ≤28 days)
Fetal or neonatal death occurring from birth through hospital discharge.
From birth through hospital discharge (expected ≤28 days)
Neonatal Resuscitation Level
Časové okno: At delivery
Level of resuscitation at birth categorized as none, stimulation only, positive pressure ventilation, or advanced resuscitation.
At delivery

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Recruitment Rate
Časové okno: Recruitment period (up to 18 months)
Proportion of eligible patients who consent to participation.
Recruitment period (up to 18 months)
Intervention Adherence
Časové okno: From admission to delivery (expected ≤72 hours)
Proportion of scheduled supplements consumed (measured as proportion of scheduled doses consumed)
From admission to delivery (expected ≤72 hours)
CGM Data Completeness
Časové okno: From admission to delivery (expected ≤72 hours)
Proportion of the intrapartum period with valid CGM data
From admission to delivery (expected ≤72 hours)
Survey Completion Rate
Časové okno: 48 hours postpartum
Proportion of participants completing postpartum surveys (LAS and BSS-R).
48 hours postpartum
Number of Maternal Healthcare Encounters
Časové okno: From hospital discharge to 6 weeks postpartum
Number of healthcare encounters including hospitalizations, emergency department visits, urgent care visits, and primary care visits.
From hospital discharge to 6 weeks postpartum
Developmental screening
Časové okno: First year of life
Development assessed using Ages and Stages Questionnaire, Third Edition (ASQ-3), a parent-completed developmental screening tool with five domains (communication, gross motor, fine motor, problem-solving, personal-social). Domain scores range from 0 to 60, with lower scores indicating greater developmental concern. This is a screening tool; scores are interpreted relative to age-specific cutoffs.
First year of life
Randomization Success
Časové okno: Recruitment period (up to 18 months)
Proportion of consented patients successfully randomized
Recruitment period (up to 18 months)
Protocol Deviations
Časové okno: Recruitment period (up to 18 months)
Number and type of deviations from the study protocol.
Recruitment period (up to 18 months)
Retention
Časové okno: From randomization through delivery hospitalization(expected ≤7 days)
Proportion of randomized participants with complete primary outcome data
From randomization through delivery hospitalization(expected ≤7 days)
Postpartum CGM Tolerability
Časové okno: Within 7 days postpartum
Structured questionnaire assessing irritation, comfort, interference, and willingness to reuse CGM using structured Likert-style responses (e.g., none/mild/moderate/severe for irritation; yes/no for willingness to use CGM again). No composite score is generated.
Within 7 days postpartum
Postpartum CGM Wear Time
Časové okno: Delivery to 7 days postpartum
Total postpartum CGM wear time (hours).
Delivery to 7 days postpartum

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Medical College of Wisconsin

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. července 2026

Primární dokončení (Odhadovaný)

30. července 2028

Dokončení studie (Odhadovaný)

30. července 2028

Termíny zápisu do studia

První předloženo

25. března 2026

První předloženo, které splnilo kritéria kontroly kvality

29. dubna 2026

První zveřejněno (Aktuální)

6. května 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

6. května 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

29. dubna 2026

Naposledy ověřeno

1. dubna 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • PRO00057233

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ano

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit